772 results match your criteria Heart Failure Clinics [Journal]


Heart Failure in Women: An Increasing Health Concern.

Heart Fail Clin 2019 Jan;15(1):xiii-xiv

Preventative Cardiology and Women's Cardiovascular Health, Division of Cardiology, The Ohio State University, 473 West 12th Avenue, Columbus, OH 43065, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.10.001DOI Listing
January 2019
1 Read

Advanced Therapies for Advanced Heart Failure in Women.

Heart Fail Clin 2019 Jan 24;15(1):97-107. Epub 2018 Oct 24.

Department of Medicine, Division of Cardiology, Center for Advanced Cardiac Care, Columbia University Medical Center, 622 West 168th Street PH1273, New York, NY 10032, USA.

Women with advanced heart failure (HF) are underrepresented in trials of short-term and durable mechanical circulatory support although they derive similar benefit. In acute HF, intensive medical and interventional therapies are effective but underutilized. The smaller, newer generation, left ventricular assist devices (LVADs) have increased the feasibility of durable support in women. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15517136183007
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2018.08.010DOI Listing
January 2019
14 Reads

Heart Failure with Preserved Ejection Fraction in Women.

Heart Fail Clin 2019 Jan;15(1):9-18

Department of Internal Medicine, Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. Electronic address:

Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent condition, particularly in women. Comorbidities, including older age, obesity, diabetes mellitus, hypertension, and hyperlipidemia, are risk factors and define phenotypic profiles of HFpEF in women. The condition has a relatively high burden of morbidity and mortality, with phenotypic profiles potentially characterizing risk of hospitalization and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.08.002DOI Listing
January 2019
8 Reads

Heart Failure in Women with Congenital Heart Disease.

Heart Fail Clin 2019 Jan 24;15(1):87-96. Epub 2018 Oct 24.

Department of Internal Medicine, Division of Cardiovascular Medicine, Emory University, Atlanta, GA, USA.

Heart failure remains the most common cause of morbidity and mortality in adults with congenital heart disease (CHD). Although gender-specific outcomes are not robust, it seems that women with CHD may be more affected by late heart failure (HF) than men. A specialized and experienced adult CHD team is required to care for these women as they age, including assessment for reversible causes of HF and in the management of pregnancy, labor, and delivery. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15517136183007
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2018.08.009DOI Listing
January 2019
6 Reads

Valvular Heart Disease and Heart Failure in Women.

Heart Fail Clin 2019 Jan;15(1):77-85

Division of Cardiology, Harvard Medical School, Massachusetts General Hospital, 55 Fruit Street Blake 256, Boston, MA 02114, USA. Electronic address:

Valvular heart disease and heart failure remain important causes of cardiovascular disease among women in the United States. Mitral regurgitation, aortic stenosis, and tricuspid regurgitation are the most common valvular lesions among men and women. This review focuses on gender differences in the epidemiology, treatment, and outcomes of mitral regurgitation, aortic stenosis, and tricuspid regurgitation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.08.008DOI Listing
January 2019
1 Read

Breast Cancer and Heart Failure.

Heart Fail Clin 2019 Jan;15(1):65-75

Department of Cardiology, Emory University School of Medicine, 1364 Clifton Road, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, 1365 Clifton Road Atlanta, GA 30322, USA.

Heart failure and breast cancer have shared risks and morbidities. Multimodality therapies for breast cancer, including conventional chemotherapy, targeted therapeutics, radiation therapy, and hormonal agents, may make patients more susceptible to asymptomatic left ventricular dysfunction and clinical heart failure during and after treatment. New or preexisting left ventricular dysfunction may lead to interruptions in cancer treatment and limit options of breast cancer systemic therapy, leading to adverse outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.08.007DOI Listing
January 2019
2 Reads

Atrial Fibrillation and Heart Failure in Women.

Heart Fail Clin 2019 Jan 24;15(1):55-64. Epub 2018 Oct 24.

Department of Medicine, Cardiology Division, Rush University Medical Center, 1725 W. Harrison Street, Room 1159, Chicago, IL 60612, USA. Electronic address:

Atrial fibrillation often occurs as a cause or consequence of heart failure. Clinical outcomes are worse when atrial fibrillation and heart failure coexist. There are important sex-related differences in the incidence, prevalence, pathophysiology, treatment, and outcomes of these patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15517136183007
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2018.08.006DOI Listing
January 2019
5 Reads

Stress-Induced Cardiomyopathy.

Heart Fail Clin 2019 Jan;15(1):41-53

Division of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, 1825 Eastchester Road, 2nd Floor Cardiology, Bronx, NY 10467, USA. Electronic address:

Stress-induced cardiomyopathy is characterized by reversible myocardial injury with distinctive regional wall motion abnormalities of the left ventricle, usually precipitated by an emotional or physical stressor. This condition has a strong predilection for older women and has a trend of increasing incidence. The diagnosis can be made based on symptoms, biomarkers, electrocardiogram, coronary angiogram, and noninvasive imaging. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15517136183007
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2018.08.005DOI Listing
January 2019
3 Reads

Peripartum Cardiomyopathy: Progress in Understanding the Etiology, Management, and Prognosis.

Heart Fail Clin 2019 Jan 25;15(1):29-39. Epub 2018 Oct 25.

Cardiovascular Medicine, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905, USA.

Occurring in approximately 1 in 1000 live births in the United States, peripartum cardiomyopathy (PPCM) is characterized by left ventricular ejection fraction reduced to less than 45% near the end of pregnancy or within the first 5 months after delivery. Although the cause of PPCM remains unclear, increasing evidence supports a complex interaction of genetic and environmental factors contributing to angiogenic imbalance, which may lead to myocardial dysfunction in a susceptible woman. This article reviews the progress that has been made regarding understanding of the cause, management, and natural history of PPCM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.08.004DOI Listing
January 2019
1 Read

Heart Failure with Reduced Ejection Fraction in Women: Epidemiology, Outcomes, and Treatment.

Heart Fail Clin 2019 Jan 24;15(1):19-27. Epub 2018 Oct 24.

Heart and Vascular Institute, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, 9500 Euclid Avenue, J3-4, Cleveland, OH 44195, USA.

There are millions of people affected by heart failure with reduced ejection fraction (HFrEF) as diagnosed with ejection fraction 40% or less by imaging. Established therapies have been proven through clinical trials on lifestyle interventions, medications, and devices for HFrEF to improve quality of life, heart function, and survival. Although there are more men than women suffering with HFrEF, there are no prospectively proven, sex-specific guideline therapies because women have been underrepresented in clinical trials. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15517136183006
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2018.08.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298793PMC
January 2019
8 Reads

Pulmonary Hypertension in Women.

Heart Fail Clin 2019 Jan 24;15(1):137-145. Epub 2018 Oct 24.

Division of Cardiovascular Medicine, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.

Prevalence of pulmonary arterial hypertension (PAH) is higher in women, and the mechanism remains unclear. Prognosis is overall better for female compared with male patients with PAH. Pregnancy is associated with significant risk, mortality, and morbidity in patients with PAH; consensus guidelines recommend against pregnancy and counsel about early termination in these patients. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15517136183007
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2018.08.013DOI Listing
January 2019
10 Reads
1.408 Impact Factor

Heart Transplantation in Women.

Heart Fail Clin 2019 Jan 24;15(1):127-135. Epub 2018 Oct 24.

Education in Heart Failure and Transplantation, Heart Failure Research, Smidt Heart Institute, Cedars-Sinai Medical Center, 8536 Wilshire Boulevard Suite 301, Los Angeles, CA 90211, USA. Electronic address:

Over the past 5 decades, heart transplantation has become an established therapy with greater quality of life and survival than expected from end-stage heart failure. Nonetheless, challenges still exist, especially for women undergoing heart transplantation. Women have greater post-transplant survival than their male counterparts but worse quality of life. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15517136183007
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2018.08.012DOI Listing
January 2019
6 Reads

Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy in Women.

Heart Fail Clin 2019 Jan;15(1):109-125

Cooper University Hospital, 1 Cooper Plaza, 3 Dorrance, Camden, NJ 08103, USA.

Implantable cardioverter-defibrillator and cardiac resynchronization therapy devices have been prescribed for patients with heart failure for several decades. Factors leading to increased usage include significant enhancements in technology and availability of multiple randomized clinical trials demonstrating their benefit with improved implementation of evidence-based guidelines. Despite these advances, gaps still exist in the utilization and referral of these devices, particularly among women. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15517136183007
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2018.08.011DOI Listing
January 2019
9 Reads

Sex-Specific Differences in Risk Factors for Development of Heart Failure in Women.

Heart Fail Clin 2019 Jan 24;15(1):1-8. Epub 2018 Oct 24.

The Ohio State University, 410 West 10th Avenue, Columbus, OH 43210, USA.

Sex specific differences exist in the impact of risk factors for the development of heart failure (HF). Addressing these differences can have an impact on prevention of HF. This article reviews sex-specific risk factors associated with development of HF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.08.001DOI Listing
January 2019
19 Reads

Preface.

Heart Fail Clin 2018 10;14(4):xiii-xiv

Cardiology Division, "Cava de' Tirreni and Amalfi Coast" Hospital, Cardiothoracic and Vascular Department-, University Hospital, Salerno, Italy; Via Pr. Amedeo, 36, Lauro, Avellino 83023, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.08.014DOI Listing
October 2018

Management of Sleep Apnea in Heart Failure.

Heart Fail Clin 2018 Oct 18;14(4):635-642. Epub 2018 Aug 18.

Department of Cardiology, Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, Sydney Street, London SW3 6NP, UK; Royal Brompton Hospital, National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LR, UK; Case Western Reserve University School of Medicine, 2109 Adelbert Rd, Cleveland, Ohio 44106, USA.

Sleep-disordered breathing (SDB) is highly prevalent in heart failure (HF). The presence of SDB in patients with HF appears to be associated with increased risk of cardiovascular morbidity and mortality. In this article, we describe the types, pathophysiology, and consequences of SDB and discuss ways in which SDB can be diagnosed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.06.008DOI Listing
October 2018

Interventional Heart Failure and Hemodynamic Monitoring.

Heart Fail Clin 2018 Oct 18;14(4):625-634. Epub 2018 Aug 18.

Department of Cardiology, Ohio State University Wexner Medical Center, 473 West 12th Avenue, Suite 200, Columbus, OH 43210-1252, USA; Interventional Cardiology, 473 West 12th Avenue, Suite 200, Columbus, OH 43210, USA. Electronic address:

Convergence of the fields of heart failure (HF) and interventional cardiology has led to the formation of a discipline referred to as interventional HF. Although the term may be applied to essentially any invasive procedure performed in patients with HF (eg, coronary angiography, percutaneous coronary intervention, invasive assessment of hemodynamics), it is more commonly reserved for the application of invasive diagnostic or therapeutic procedures to improve the clinical decision-making, functional status, and outcomes of HF patients. This article reviews developing modalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.06.007DOI Listing
October 2018
1 Read

Palliative Therapy in Heart Failure.

Heart Fail Clin 2018 Oct 16;14(4):617-624. Epub 2018 Aug 16.

Division of Palliative Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, McCampbell Hall, 5th Floor, 1581 Dodd Drive, Columbus, OH 43210, USA. Electronic address:

Cardiac palliative care is a multidisciplinary approach provided alongside standard heart failure management to improve a patient's quality of life. In this article the authors review the role of palliative care in heart failure management, including recent studies exploring the benefits of palliative care consultation in the inpatient and outpatient setting. They also discuss approaches to goals-of-care discussions and challenges providing end-of-life care in this patient population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.06.011DOI Listing
October 2018

Current Status of Inotropes in Heart Failure.

Heart Fail Clin 2018 Oct 17;14(4):601-616. Epub 2018 Aug 17.

Division of Cardiovascular Medicine, Harrington Heart & Vascular Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

Inotropes are medications that improve the contractility of the heart and are used in patients with low cardiac output or evidence of end-organ dysfunction. Since their initial discovery, inotropes have held promise in alleviating symptoms and potentially increasing longevity in such patients. Decades of intensive study have further elucidated the benefits and risks of using inotropes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.06.010DOI Listing
October 2018
2 Reads

Mitral Valve Surgery for Congestive Heart Failure.

Heart Fail Clin 2018 Oct 18;14(4):585-600. Epub 2018 Aug 18.

Senior Associate Consultant, Department of Cardiovascular Surgery, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address:

Mitral valve diseases are common causes of congestive heart failure. Chronic primary and secondary (functional) mitral valve regurgitation are the most common reasons. Valve repair for primary mitral regurgitation cures mitral valve disease, whereas in functional regurgitation, mitral valve repair is associated with high failure rates secondary to persistent/progressive ventricular dysfunction and remodeling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.06.006DOI Listing
October 2018
1 Read

Short-Term Circulatory and Right Ventricle Support in Cardiogenic Shock: Extracorporeal Membrane Oxygenation, Tandem Heart, CentriMag, and Impella.

Heart Fail Clin 2018 Oct 20;14(4):579-583. Epub 2018 Aug 20.

Division of Cardiac Surgery, Department of Surgery, Johns Hopkins Hospital, 600 N Wolfe Street, Baltimore, MD 21234, USA.

Severe right ventricular (RV) failure is a significant cause of morbidity and mortality, with an in-hospital mortality rate up to 70% to 75%. Medical management is employed and is successful for most of these patients. However, a small percentage of patients will continue to have persistent RV failure, for which mechanical support is used for management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.06.014DOI Listing
October 2018
3 Reads

Management of Heart Failure in Adult Congenital Heart Disease.

Heart Fail Clin 2018 Oct 20;14(4):569-577. Epub 2018 Aug 20.

Department of Physiology and Cell Biology, The Ohio State University, Nationwide Children's Hospital, Davis Heart and Lung Research Institute, 473 West 12th Avenue Suite 200, Columbus, OH 43210, USA.

There are more than 1 million adults with congenital heart disease (ACHD) in the United States. Heart failure (HF) is the most common late cardiovascular complication. These patients are challenging to manage given their diverse presentation, anatomy, and complex hemodynamics. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15517136183005
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2018.06.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204213PMC
October 2018
13 Reads

Management of Cancer Therapeutics-Related Cardiac Dysfunction.

Heart Fail Clin 2018 Oct 18;14(4):553-567. Epub 2018 Aug 18.

Division of Cardiovascular Diseases, Department of Internal Medicine, The Ohio State University, 410 West 10th, Avenue, Columbus, OH 43210, USA.

Improvements in detection and treatment of cancer have resulted in a significant increase in cancer survivors. However, cancer survivorship comes with long-term risk of adverse effects of cancer therapies, including cardiomyopathy, heart failure, arrhythmias, ischemic heart disease, atherosclerosis, thrombosis, and hypertension. There is a renewed interest in understanding the pathophysiology of cancer therapeuticserelated cardiac dysfunction. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15517136183005
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2018.06.004DOI Listing
October 2018
16 Reads

Management of Pulmonary Hypertension: Associated with Left Heart Disease.

Authors:
Veronica Franco

Heart Fail Clin 2018 Oct 18;14(4):545-551. Epub 2018 Aug 18.

Division of Cardiovascular Disease, Pulmonary Hypertension Program, Advanced Heart Failure, LVAD and Transplantation Program, The Ohio State University, DHLRI Suite 200, 473 West 12th Avenue, Columbus, OH 43210, USA. Electronic address:

Pulmonary hypertension (PH) due to left heart disease, or WHO group 2 PH, is the most frequent cause of PH. It affects approximately 50% to 60% of patients with heart failure with preserved ejection fraction as well as 60% of those with heart failure with reduced ejection fraction and contributes significantly to disease progression and unfavorable outcomes. The diagnosis of PH is associated with poor prognosis and significant morbidity and mortality. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15517136183005
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2018.06.009DOI Listing
October 2018
1 Read
1.410 Impact Factor

Intravenous Iron Therapy in Heart Failure.

Heart Fail Clin 2018 Oct 18;14(4):537-543. Epub 2018 Aug 18.

Advanced Heart Failure and Cardiac Transplantation, St. Vincent Medical Group, 8333 Naab Road, Suite 400, Indianapolis, IN 46260, USA.

Iron deficiency anemia is both a comorbid condition and an indicator of poor prognosis in heart failure. The mechanisms by which this occurs are multiple and complex. Recent robust randomized clinical trials have shown significant improvements in quality of life and rates of hospitalization with intravenous repletion of iron. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15517136183005
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2018.06.003DOI Listing
October 2018
3 Reads

Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction.

Heart Fail Clin 2018 Oct 18;14(4):525-535. Epub 2018 Aug 18.

Department of Medicine, Section of Cardiology, Baylor College of Medicine and Michael E. DeBakey VA Medical Center, 2002 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address:

More than 50% of patients with clinical heart failure have a preserved ejection fraction. Despite mortality that is similar to or slightly lower than heart failure with reduced ejection fraction, trials to date have not shown a therapy that imparts a mortality benefit in heart failure with preserved ejection fraction (HFpEF). HFpEF represents a heterogeneous disorder with a complex pathophysiologic basis, and this may contribute to the negative results in clinical trials. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15517136183005
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2018.06.002DOI Listing
October 2018
7 Reads

Ultrafiltration for the Treatment of Acute Heart Failure.

Authors:
Sitaramesh Emani

Heart Fail Clin 2018 Oct 20;14(4):517-524. Epub 2018 Aug 20.

Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, 473 West 12th Avenue, Suite 200 DHLRI, Columbus, OH 43210, USA. Electronic address:

Ultrafiltration (UF) mechanically removes excess fluid volume through an extracorporeal circuit and has been applied to clinical situations in which volume removal is the mainstay of therapy. Because of this ability, UF serves as an enticing method to treat acute heart failure (AHF) in which most symptoms are driven by congestion due to excess volume. Additional physiologic properties of UF and the biochemical composition of the extracted fluid confer additional theoretic benefits in the treatment of AHF. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15517136183006
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2018.06.013DOI Listing
October 2018
7 Reads

Growth Hormone Therapy in Heart Failure.

Heart Fail Clin 2018 Oct 17;14(4):501-515. Epub 2018 Aug 17.

Department of Translational Medical Sciences, Federico II University, School of Medicine, Via Pansini 5, Naples, 80131, Italy; Interdisciplinary Research Centre in Biomedical Materials, Federico II University, Naples, 80100, Italy. Electronic address:

Several studies have shown that growth hormone (GH) deficiency is common in chronic heart failure and is associated with impaired functional capacity and poor outcomes. Data derived from animal models showed beneficial effects of GH treatment on peripheral vascular resistance, cardiac function, and survival. Despite this solid background, when translated onto the clinical field, these results did not lead to unequivocal results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.05.002DOI Listing
October 2018
12 Reads
1.410 Impact Factor

The Use and Indication of Ivabradine in Heart Failure.

Heart Fail Clin 2018 Oct 18;14(4):493-500. Epub 2018 Aug 18.

Division of Cardiovascular Medicine, The Ohio state University Wexner Medical Center, 473 W12th Avenue, Columbus, OH 43210, USA. Electronic address:

Heart failure affects more than 6 million people in the United States each year and the prognosis is poor. The elevated heart rate in heart failure patents is problematic, because it increases myocardial oxygen demand, decreases myocardial perfusion, and has been associated with increased rates of hospitalization and mortality. For these reasons, heart rate reduction has long been a therapeutic target in heart failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.06.001DOI Listing
October 2018
1 Read

Sacubitril/Valsartan: The Newest Neurohormonal Blocker for Guideline-Directed Medical Therapy for Heart Failure.

Heart Fail Clin 2018 Oct 17;14(4):479-491. Epub 2018 Aug 17.

Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, 200 Davis Heart and Lung Research Institute (HLRI), 473 West 12th Avenue, Columbus, OH 43210-1252, USA. Electronic address:

The burden of heart failure is projected to increase over the next decade; it is predicted that 1 in every 33 Americans will be affected by heart failure. Given that heart failure currently results in more than 1 million hospitalizations every year and the estimated 5-year mortality is approximately 50%, therapies that will improve survival and the economic burden are urgently needed. It is anticipated that the cost of managing heart failure is going to be approximately $70 billion in 2030. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.06.012DOI Listing
October 2018

Erratum.

Authors:

Heart Fail Clin 2018 07;14(3):xvii

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.03.002DOI Listing
July 2018
1 Read

The RIGHT Heart International NETwork (RIGHT-NET): A Road Map Through the Right Heart-Pulmonary Circulation Unit.

Heart Fail Clin 2018 07;14(3):xix-xx

Institute of Clinical Physiology-, National Research Council, via Moruzzi 1, 56124 Pisa, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.05.001DOI Listing
July 2018
9 Reads

Right Heart Catheterization for the Diagnosis of Pulmonary Hypertension: Controversies and Practical Issues.

Heart Fail Clin 2018 Jul;14(3):467-477

Department of Cardiology, Erasme University Hospital, University of Brussels, Route de Lennik 808, Brussels 1070, Belgium.

Right heart catheterization (RHC) is the gold standard for the diagnosis and classification of pulmonary hypertension. Significant expertise is required for safely performing a full RHC and for the acquisition of reliable and reproducible information. Physicians performing an RHC should have adequate training not only in vascular access, catheter insertion, and manipulation but also in the interpretation of waveforms, potential pitfalls, and strict quality control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.03.011DOI Listing
July 2018
1 Read

The Right Heart International Network (RIGHT-NET): Rationale, Objectives, Methodology, and Clinical Implications.

Heart Fail Clin 2018 Jul;14(3):443-465

Cardiology Division, Heart Department, "Cava de' Tirreni and Amalfi Coast" Hospital, University of Salerno, Salerno, Italy. Electronic address:

The Right Heart International Network is a multicenter international study aiming to prospectively collect exercise Doppler echocardiography tests of the right heart pulmonary circulation unit (RHPCU) in large cohorts of healthy subjects, elite athletes, and individuals at risk of or with overt pulmonary hypertension. It is going to provide standardization of exercise stress echocardiography of RHPCU and explore the full physiopathologic response. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.03.010DOI Listing
July 2018
17 Reads

The Right Heart-Pulmonary Circulation Unit and Left Heart Valve Disease.

Heart Fail Clin 2018 Jul;14(3):431-442

GIGA Cardiovascular Sciences, University Hospital Sart Tilman, 4000 Liège, Belgium; Heart Valve Clinic, Department of Cardiology, University Hospital Sart Tilman, 4000 Liège, Belgium; Gruppo Villa Maria Care and Research, Anthea Hospital, VIA C. ROSALBA, 35/37 70124 Bari, Italy. Electronic address:

Valvular heart disease (VHD) is frequently accompanied by pulmonary hypertension (PH). In asymptomatic patients, PH is rare, although the exact prevalence is unknown and mainly stems from the severity of the VHD and the presence of diastolic dysfunction. PH can also be depicted during exercise echocardiography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.03.009DOI Listing
July 2018
5 Reads

Exercise Training and Rehabilitation in Pulmonary Hypertension.

Heart Fail Clin 2018 Jul;14(3):425-430

Department of Pneumology, Centre for Pulmonary Hypertension, Thoraxklinik at Heidelberg University Hospital, Röntgenstraße 1, Heidelberg 69126, Germany; German Center of Lung Research (DZL), TLRC Heidelberg, Germany. Electronic address:

Within the last years, exercise training and rehabilitation as add-on to medical treatment has become an emerging field in pulmonary hypertension. Owing to the beneficial effects of exercise training in pulmonary hypertension, the new European Respiratory Society/European Society of Cardiology guidelines for pulmonary hypertension recommended a supervised and closely monitored exercise and respiratory training/rehabilitation as add-on to medical therapy (class IIa, level of evidence B). In this article, different training modalities, effects of exercise training, possible pathobiological mechanisms of action, and future research questions are discussed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.03.008DOI Listing

Chronic Right Heart Failure: Expanding Prevalence and Challenges in Outpatient Management.

Heart Fail Clin 2018 Jul;14(3):413-423

Department of Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Yale University School of Medicine, New Haven, CT, USA. Electronic address:

Right heart failure is caused by right heart dysfunction resulting in suboptimal stroke volume to supply the pulmonary circulation. Therapeutic developments mean that patients with acute right heart failure survive to hospital discharge and live with chronic right heart failure. Chronic right heart failure management aims to reduce afterload, optimize preload, and support contractility, with the best evidence available in vascular targeted therapy for pulmonary arterial hypertension. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.03.007DOI Listing
July 2018
34 Reads

Pulmonary Hypertension Related to Chronic Obstructive Pulmonary Disease and Diffuse Parenchymal Lung Disease: A Focus on Right Ventricular (Dys)Function.

Heart Fail Clin 2018 Jul;14(3):403-411

Pulmonary and Critical Care Medicine, University of California, Los Angeles, David Geffen School of Medicine, 10833 Le Conte Avenue, Room 37-131 CHS, Box 951690, Los Angeles, CA 90095, USA. Electronic address:

Diffuse pulmonary lung disease and chronic obstructive pulmonary disease is a heterogeneous population that can manifest pulmonary hypertension. These subgroups are classified as primarily World Health Organization group 3. Available data suggest that the impact of pulmonary hypertension targeted therapy in diffuse pulmonary lung disease and chronic obstructive pulmonary disease is limited and survival is poor despite attempted treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.03.006DOI Listing
July 2018
4 Reads

Biomarkers in Pulmonary Hypertension.

Heart Fail Clin 2018 Jul;14(3):393-402

Department of Translational Medical Sciences, University Federico II of Naples, "Federico II" University-School of Medicine, Via Pansini 5, Naples 80131, Italy; Interdisciplinary Research Centre in Biomedical Materials (CRIB), Via Pansini 5, Napoli 80131, Italy. Electronic address:

Biomarkers are tools in pulmonary hypertension (PH) management. They may address risk assessment, disease progression, response to medical and surgical therapy, risk of right heart failure, and prognosis. The activation of molecular pathways is the pathophysiological underpinning of the biomarkers assessed in peripheral venous blood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.03.005DOI Listing
July 2018
6 Reads
1.410 Impact Factor

Imaging the Right Heart-Pulmonary Circulation Unit: The Role of MRI and Computed Tomography.

Heart Fail Clin 2018 Jul;14(3):377-391

Heart Department, Cardiology Division, "Cava de' Tirreni and Amalfi Coast" Hospital, University of Salerno, Salerno 84013, Italy.

The different components of the right heart pulmonary circulation unit can be investigated by MRI and computed tomography. MRI has clear advantages over echocardiography for accurate definition of right heart function and structure and to derive functional information regarding the pulmonary vasculature. Computed tomography is superior for the assessment of parenchymal and vascular pathologies of the lung with indications in the diagnostic work-up of pulmonary hypertension, but with more limited capability to evaluate right ventricular function and in deriving pulmonary hemodynamics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.03.004DOI Listing
July 2018
2 Reads

Imaging the Right Heart-Pulmonary Circulation Unit: The Role of Ultrasound.

Heart Fail Clin 2018 Jul;14(3):361-376

Service de cardiologie, institut Lorrain du cœur et des vaisseaux Louis-Mathieu, centre hospitalier universitaire de Nancy, 4, rue du Morvan, 54500 Vandœuvre-lès-Nancy, France.

Echocardiography is the first step in imaging the right heart pulmonary circulation unit (RH-PCU), and the only one to allow its complete morphologic, functional, and hemodynamic analysis in all clinical scenarios. Right ventricular (RV) function is not only the consequence of its intrinsic contractile function (morphology and contractility) but also highly dependent on preload, afterload, and ventricular interdependence. Comprehensive echocardiographic examination of RH-PCU allows insight into intrinsic and extrinsic factors of RV function. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.03.003DOI Listing
July 2018
1 Read

Invasive and Noninvasive Evaluation for the Diagnosis of Pulmonary Hypertension: How to Use and How to Combine Them.

Heart Fail Clin 2018 Jul;14(3):353-360

Azrieli Heart Center, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

The etiologic diagnosis of pulmonary hypertension (PH) may be very challenging. Right-heart catheterization (RHC) in isolation cannot classify a precapillary PH patient into group 1, 3, 4, or 5. Moreover, RHC may be not sufficient for reaching a definitive differential diagnosis of precapillary or postcapillary PH if hemodynamic data are not integrated in clinical context and combined with information gleaned from noninvasive imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.02.010DOI Listing
July 2018
1 Read

Chronic Thromboembolic Pulmonary Hypertension.

Heart Fail Clin 2018 Jul;14(3):339-351

Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Rhode Island Hospital, 593 Eddy Street, POB Suite 224, Providence, RI 02903, USA. Electronic address:

Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct type of pulmonary hypertensive disease, characterized by incomplete or abnormal resolution of acute pulmonary embolism such that residual emboli become organized and fibrotic. CTEPH can occur in patients without a prior history of venous thromboembolism, and is diagnosed based on precapillary pulmonary hypertension on right heart catheterization with evidence of chronic emboli on ventilation/perfusion scan, chest imaging, or pulmonary angiogram. Pulmonary endarterectomy (PEA) is often curative, and results in improved survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.02.009DOI Listing
July 2018
5 Reads

Right Heart-Pulmonary Circulation at High Altitude and the Development of Subclinical Pulmonary Interstitial Edema.

Authors:
Lorenza Pratali

Heart Fail Clin 2018 Jul;14(3):333-337

Department of Institute of Clinical Physiology, National research Council, Via Moruzzi 1, Pisa 56214, Italy. Electronic address:

Most healthy subjects can develop a subclinical interstitial pulmonary edema that is a complex and multifactor phenomenon, still with unanswered questions, and might be one line of defense against the development of severe symptomatic lung edema. Whether the acute, reversible increase in lung fluid content is really an innocent and benign part of the adaptation to extreme physiologic condition or rather the clinically relevant marker of an individual vulnerability to life-threatening high altitude pulmonary edema remains to be established in future studies. Thus the question if encouraging more conservative habits to climb is right or not remains open. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15517136183002
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2018.02.008DOI Listing
July 2018
8 Reads

Pulmonary Hypertension: The Role of Lung Transplantation.

Heart Fail Clin 2018 Jul;14(3):327-331

Lung Institute, University of Arizona, Banner University Medical Center, 755 E. McDowell Road, 3rd Floor, Phoenix, AZ 85006, USA. Electronic address:

Despite advances in targeted medical therapy, pulmonary arterial hypertension (PAH) remains a fatal disease because of progressive right ventricular dysfunction. For patients who are refractory to medical therapy, heart-lung and lung transplantation are important treatment options. Because of longer waiting time, surgical interventions including extracorporeal lung support and atrial septostomy can be used in PAH patients bridging to transplantation. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15517136183002
Publisher Site
http://dx.doi.org/10.1016/j.hfc.2018.02.007DOI Listing
July 2018
5 Reads

Right Heart-Pulmonary Circulation Unit in Cardiomyopathies and Storage Diseases.

Heart Fail Clin 2018 Jul;14(3):311-326

Department of Advanced Biomedical Sciences, Federico II University of Naples, Via Bianchi, Naples 80100, Italy.

Cardiomyopathies (CM) are a heterogeneous group of muscle heart diseases, divided into 3 main categories (dilated, hypertrophic, and restrictive). In addition to these subgroups, athlete's heart and hypertensive cardiopathy are both the result of heart adaptation to increased loading conditions, making it possible to include them in the CM group. Right heart involvement is clear in some CM as arrhythmogenic CM, carcinoid syndrome, and endomyocardial fibrosis, whereas in others, like hypertrophic or dilated CM, it is known that the right heart has a prognostic impact but less clear is its pathogenic role. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.03.001DOI Listing
July 2018
6 Reads
1.410 Impact Factor

Pulmonary Hypertension and Heart Failure: A Dangerous Liaison.

Authors:
Marco Guazzi

Heart Fail Clin 2018 Jul;14(3):297-309

Heart Failure Unit, IRCCS Policlinico San Donato, Piazza E. Malan 2, San Donato Milanese, Milano 20097, Italy. Electronic address:

Pulmonary hypertension (PH) is a common hemodynamic evolution of heart failure (HF) with preserved or reduced ejection fraction, responsible for congestion, symptoms worsening, exercise limitation, and negative outcome. In HF of any origin, PH develops in response to a passive backward pressure transmission as result of increased left atrial pressure. Sustained pressure injury and chronic venous congestion can trigger pulmonary vasoconstriction and vascular remodeling, leading to irreversible pulmonary vascular disease, right ventricular hypertrophy, and failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.02.006DOI Listing

Right Heart-Pulmonary Circulation Unit in Congenital Heart Diseases.

Heart Fail Clin 2018 Jul;14(3):283-295

Royal Brompton and Harefield Trust, London, UK. Electronic address:

The right ventricle plays a major role in congenital heart disease. This article describes the right ventricular mechanics in some selected congenital heart diseases affecting the right ventricle in different ways: tetralogy of Fallot, Ebstein anomaly, and the systemic right ventricle. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.02.005DOI Listing
July 2018
3 Reads

Pulmonary Circulation on the Crossroads Between the Left and Right Heart in Systemic Sclerosis: A Clinical Challenge for Cardiologists and Rheumatologists.

Heart Fail Clin 2018 Jul;14(3):271-281

Department of Experimental and Clinical Medicine, Azienda Ospedaliera Universitaria Careggi, Largo Brambilla, 3, 50134 Florence, Italy.

Involvement of the right heart-pulmonary circulation system in systemic sclerosis is a typical feature, with critical prognostic implications. Pulmonary hypertension may occur in association with interstitial lung disease or as a result of an isolated pulmonary vascular disease that may affect both the precapillary arterioles and the postcapillary venules, as well as a consequence of left heart involvement. These apparently different phenotypes often underlie a significant pathophysiologic overlap, which makes the diagnosis and management of these patients highly complex and uncertain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.02.004DOI Listing

Pulmonary Arterial Hypertension.

Heart Fail Clin 2018 Jul;14(3):255-269

Department of Medicine, Intermountain Medical Center, 5121 South Cottonwood Street, Building 2, Suite 307, Murray, UT 84107, USA; Pulmonary Division, University of Utah, 24 North 1900 East, Wintrobe Building, Room 701, Salt Lake City, UT 84132, USA. Electronic address:

This article provides an overview of pulmonary arterial hypertension (PAH), beginning with the initial pathologic recognition of pulmonary hypertension more than 100 years ago and progressing to the current diagnostic categorization of PAH. It reviews the epidemiology, pathophysiology, genetics, and modern treatment of PAH. The article discusses several important recent studies that have highlighted the importance of new management strategies, including serial risk assessment and combination pharmacotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hfc.2018.02.003DOI Listing
July 2018
1 Read